Lonza: x-ray powder diffraction addition at Swiss site
Pharma manufacturing specialist Lonza reportedly has expanded the range of particle engineering services offered at its Monteggio site with the introduction of X-ray powder diffraction (XRPD) capability. This rapid analytical technique is intended to provide additional information about the polymorph and solid-state properties of active pharmaceutical ingredients (APIs).
Salvatore Mercuri, Lonza’s associate director of new product introduction and MSAT, commented, “The implementation of XRPD provides additional analytical information, highlighting differences in the solid state of materials before and after micronization and determining whether additional processing is needed. The XRPD improves our ability to detect solid state changes induced by the micronization process early in development and allows the problem to be properly addressed before the process is defined; this will ensure that our processes continue to obtain stable products suitable for further processing and formulation.”